Curated News
By: NewsRamp Editorial Staff
November 14, 2024

Silexion Therapeutics Reports Q3 Financial Results and Business Update

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackView History of this news story on GitHub Github
Source News Release

TLDR

  • Silexion completed a strategic business combination, gaining access to greater capital for advancing clinical pipeline.
  • Silexion's first-generation candidate, LODER, demonstrated a 56% objective response rate in Phase 2 trial for non-resectable pancreatic cancer.
  • Silexion's advancements in RNAi therapies have the potential to improve surgical outcomes and overall survival for patients with challenging pancreatic cancer.
  • Silexion's next-generation candidate, SIL-204, demonstrated substantial anti-tumor effects and enhanced stability in preclinical studies.

Impact - Why it Matters

This news matters as it highlights the significant progress made by Silexion Therapeutics in developing innovative RNA interference therapies for challenging cancers. The promising results of LODER™ and SIL-204 demonstrate the potential to improve treatment outcomes for patients with KRAS-driven cancers. The company's strategic milestones and financial updates provide valuable insight into its growth and commitment to advancing cancer therapeutics.

Summary

Silexion Therapeutics Corp. (NASDAQ: SLXN) reported its financial results for the third quarter ended September 30, 2024, and provided an update on recent business developments. The company completed its business combination with Moringa Acquisition Corp, becoming a publicly traded company on Nasdaq. Silexion's first-generation candidate, LODER™, demonstrated promise in clinical settings for non-resectable pancreatic cancer, while its next-generation candidate, SIL-204, showed substantial anti-tumor effects and enhanced stability in preclinical studies. The company is preparing SIL-204 for toxicology studies and plans to initiate Phase 2/3 clinical trials by the first half of 2026, targeting LAPC. Silexion also plans to initiate preclinical studies for SIL-204 in colorectal cancer models.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Silexion Therapeutics Reports Q3 Financial Results and Business Update

blockchain registration record for the source press release.